Wegovy vs Saxenda weight loss treatments offer a new way for individuals struggling to shed stubborn extra pounds. But understanding how they differ, and which might suit your goals best can feel overwhelming.
Table of Contents
We will simplify the science, compare their effectiveness, and break down research-backed facts to help you make a more informed decision.
Understanding The Basics of Wegovy vs Saxenda Weight Loss
Both Wegovy and Saxenda are injectable prescription medications used to support weight management. They are part of a group known as GLP-1 receptor agonists. These medicines act by imitating the effects of a natural hormone called GLP-1 in your body that helps control appetite, food intake, and insulin levels. They help you feel full sooner and reduce hunger cues.
While they work in similar ways, they differ in formulation, dosage, frequency of injection, and clinical outcomes. Let’s walk through those differences, side effects and actual user results so you can see which might be more suitable for your journey.
Weekly vs Daily Injections
A big lifestyle consideration for many people is how often they need to take their medication.
Saxenda (liraglutide) has a shorter half-life and needs daily dosing.
Wegovy (semaglutide) lasts longer in your system and can be taken weekly.
This can make Wegovy more appealing to people who prefer fewer interruptions in their routine. In real life, convenience can impact consistency, which in turn affects results. People are more likely to stick to a treatment plan if it fits into their lifestyle easily.
However, Saxenda may offer more flexibility if you want to adjust doses quickly or prefer shorter-acting medications.
Weight Loss Results: Wegovy vs Saxenda Studies
Numerous global studies have compared Wegovy vs Saxenda weight loss outcomes, and the findings are clear.
Wegovy Clinical Trials
The Wegovy vs Saxenda weight loss discussion often leads to comparisons of their clinical trial outcomes, especially the Semaglutide Treatment Effect in People with Obesity (STEP) program.
The STEP program comprises a series of pivotal trials evaluating the effectiveness and tolerability of once-weekly semaglutide 2.4 mg for supporting weight reduction in adults with overweight or obesity.
STEP 1 included 1961 adults with a BMI >30 or >27 with a comorbidity and lasted 68 weeks. Participants receiving semaglutide 2.4 mg experienced a significant mean weight loss of 14.9% compared to only 2.4% in the placebo group.(1)
STEP 2 conducted with 1210 adults with type 2 diabetes and a BMI of >27, also spanned 68 weeks. This trial compared different doses of semaglutide, and the 2.4 mg group saw a mean weight loss of 9.6%, significantly more than the 3.4 % in the placebo group. This illustrates how semaglutide can aid those with comorbid conditions.
In STEP 3, 611 adults with a BMI >30 or >27 and at least one comorbidity participated in the 68 week trial. Those receiving semaglutide 2.4 mg achieved, a mean weight loss of 16% for outpacing the 5.7% loss seen in the placebo group.(2)
Lastly, STEP 4 involved 803 adults who underwent a 20-week open-label run-in before being randomised into a 48-week trial.(3) Of those who continued on semaglutide, participants saw an additional 7.9% weight loss, while those switched to placebo regained 6.9% of the weight they had lost.
Saxenda Clinical Trials
When comparing Wegovy vs Saxenda weight loss, it is important to look at the SCALE trials, which investigated the weight loss effects of liraglutide 3.0 mg, the active ingredient in Saxenda. In the SCALE Obesity and Prediabetes trial, over 3,731 adults with obesity or overweight and comorbidities were studied for 56 weeks.
Participants treated with liraglutide(4) 3.0 mg lost an average of 8.4% of their body weight, while those on placebo lost around 2.6%. Notably, 63% of the liraglutide group lost at least 5% of their weight.
In the SCALE Diabetes trial,(5) around 846 individuals with type 2 diabetes participated for 56 weeks. Those using liraglutide 3.0 mg lost about 6% of their body weight, in contrast to 2% in the placebo group.
Moreover, the SCALE Maintenance trial involved 422 adults who had already lost at least 5% of their initial weight through diet and exercise. Over 56 weeks, those who continued on liraglutide maintained their weight loss better and even lost more.
This evidence further reinforces the role of Saxenda in long-term weight maintenance and positions it as a meaningful contender in the Wegovy vs Saxenda weight loss area.
Key Findings
When comparing Wegovy vs Saxenda weight loss, Wegovy’s trials were longer (68 weeks) but had smaller sample sizes than Saxenda’s 56 weeks studies. Wegovy showed superior weight loss results, averaging 9.9% to 18.2%, while Saxenda ranged from 5.7% to 8.4%.
Common Side Effects Comparison
When looking at Wegovy vs Saxenda weight loss, it is equally important to understand how both medications affect the body beyond just shedding kilos. Both drugs tend to produce similar side effects mostly related to the digestive system.
In a 2022 trial comparing Wegovy vs Saxenda weight loss, 27% of liraglutide users stopped due to side effects, versus 13.5% on semaglutide.(6) JAMA suggests liraglutide’s shorter half-life may trigger a sharper hunger return. Gastrointestinal issues affected 84.1% with semaglutide and 82.7% with liraglutide.
Saxenda
In clinical trials, Saxenda users reported nausea in 39% of cases, followed by diarrhoea (21%), constipation (19%), and vomiting (16%). Other issues like headache, indigestion, and injection site reactions were also noted.
Wegovy
Wegovy had a slightly higher percentage, with 44% experiencing nausea, 30% diarrhoea, and 24% each for vomiting and constipation. Less common complaints included fatigue, bloating, and dizziness.
Boxed Warning
Another crucial note in the Wegovy vs Saxenda weight loss comparison is the safety warning. Both drugs carry a boxed warning due to an observed risk of thyroid tumours in animal studies. People with a personal and family history of these two conditions should avoid these medications:
- Medullary thyroid carcinoma
- Multiple Endocrine Neoplasia type 2 (MEN 2)
Insurance Coverage and Cost Considerations
Access to Saxenda or Wegovy may depend on national health guidelines in many European countries. When comparing Wegovy vs Saxenda weight loss, insurance coverage and cost play a big role. In Europe, coverage varies by country.
For example, the UK reimburses Wegovy under NICE guidelines based on BMI and comorbidities. Saxenda may be covered in Ireland under the Drugs Payment Scheme for patients with high BMI and cardiovascular risks.
Conclusion
Choosing between Wegovy vs Saxenda weight loss is not a matter of which is better. It is about what works best for you. Thanks to recent breakthroughs in medical research, medicines like Wegovy and Saxenda offer hope to millions struggling with obesity and metabolic health diseases across Europe.
If you are exploring options and need a simple, secure way to connect with doctors and pharmacies online, Transtoyou is here to facilitate the journey. Now you can consult doctors and get medicines from the comfort of your home.
Disclaimer
The information in this article is intended for informational purposes and not as a substitute for professional medical advice. Always consult a physician or other qualified healthcare provider for specific questions about your health.
